Becton, Dickinson and Company $BDX Stock: Farmers & Merchants Investments Inc. Raises Position

Posted by Brenda Bartman on Oct 24th, 2026

Farmers & Merchants Investments Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 42.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,092 shares of the medical instruments supplier’s stock after purchasing an additional 7,747 shares during the period. Farmers & Merchants Investments Inc.’s holdings in Becton, Dickinson and Company were worth $4,670,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BDX. TD Waterhouse Canada Inc. raised its position in shares of Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after buying an additional 14,077 shares during the last quarter. Northside Capital Management LLC increased its stake in shares of Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after acquiring an additional 9,494 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 35.0% in the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the period. Beverly Hills Private Wealth LLC acquired a new stake in Becton, Dickinson and Company during the second quarter worth $3,353,000. Finally, Wealthfront Advisers LLC purchased a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $2,567,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7%

NYSE:BDX opened at $198.96 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $185.41 and its two-hundred day moving average is $165.10. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The company has a market cap of $54.82 billion, a PE ratio of 15.42, a P/E/G ratio of 13.51 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the business posted $3.68 EPS. The business’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last three months. 0.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BDX. Barclays assumed coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Wolfe Research initiated coverage on Becton, Dickinson and Company in a research note on Tuesday. They set an “outperform” rating on the stock. Finally, Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Get Our Latest Analysis on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.